Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 14/20 | 0.60 |
| ▸ | RARB | P10826 | 13/20 | 0.60 |
| ▸ | RARG | P13631 | 13/20 | 0.60 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.42 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.42 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.42 |
| ▸ | TTR | P02766 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7730271 | 0.91 | RARA (0.51) | RARARARBRARGCSNK2A2CSNK2B | |
| SCHEMBL7619645 | 0.90 | RARA (0.63) | RARARARBRARG | |
| SCHEMBL7618381 | 0.90 | RARA (0.53) | RARARARBRARGCSNK2A2CSNK2B | |
| SCHEMBL7623083 | 0.90 | RARA (0.63) | RARARARBRARG | |
| SCHEMBL7619622 | 0.89 | RARA (0.49) | RARARARBRARGCSNK2A2CSNK2B | |
| SCHEMBL7727053 | 0.88 | RARA (0.48) | RARARARBRARGCSNK2A2CSNK2B | |
| SCHEMBL8151617 | 0.87 | RARB (0.51) | RARARARBRARGCSNK2A2CSNK2B | |
| SCHEMBL7720459 | 0.86 | RARB (0.47) | RARARARBRARG | |
| SCHEMBL7621722 | 0.84 | RARA (0.53) | RARARARBRARGCSNK2A2CSNK2B | |
| SCHEMBL7618545 | 0.82 | TNKS (0.48) | RARARARBRARGTTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6258811-B1 | ADMINISTERING RETINOIC ACID RECEPTOR AGONIST | EISAI CO., LTD. (JP) | 2001-07-10 | — | — | US | claimed |
| EP-1025857-A1 | RETINOIC ACID AGONISTS AS PREVENTIVE AND THERAPEUTIC AGENTS FOR NEPHRITIS | Eisai Co., Ltd. (JP) | 2000-08-09 | — | — | EP | claimed |
| EP-0930075-A1 | METHODS FOR PREVENTING, INHIBITING OR TREATING GRAFT REJECTION REACTIONS IN GRAFT-VERSUS-HOST DISEASE (GVHD) AND ORGAN TRANSPLANTATION | Eisai Co., Ltd. (JP) | 1999-07-21 | — | — | EP | claimed |
| US-20210130337-A1 | Bicycloheteroaryl-Heteroaryl-Benzoic Acid Compounds as Retinoic Acid Receptor Beta (RARBeta) Agonists | KING'S COLLEGE LONDON (GB) | 2021-05-06 | — | — | US | disclosed |
| US-10752616-B2 | Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists | KING'S COLLEGE LONDON (GB) | 2020-08-25 | — | — | US | disclosed |
| US-20200131165-A1 | Bicycloheteroaryl-Heteroaryl-Benzoic Acid Compounds as Retinoic Acid Receptor Beta (RARBeta) Agonists | KING'S COLLEGE LONDON (GB) | 2020-04-30 | — | — | US | disclosed |
| US-10385044-B2 | Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists | KING'S COLLEGE LONDON (GB) | 2019-08-20 | — | — | US | disclosed |
| US-9994559-B2 | Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists | KING'S COLLEGE LONDON (GB) | 2018-06-12 | — | — | US | disclosed |
| US-9994559-B2 | Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists | KING'S COLLEGE LONDON (GB) | 2018-06-12 | — | — | US | disclosed |
| US-20170327489-A1 | Bicycloheteroaryl-Heteroaryl-Benzoic Acid Compounds as Retinoic Acid Receptor Beta (RARBeta) Agonists | KING'S COLLEGE LONDON (GB) | 2017-11-16 | — | — | US | disclosed |
| US-20170327489-A1 | Bicycloheteroaryl-Heteroaryl-Benzoic Acid Compounds as Retinoic Acid Receptor Beta (RARBeta) Agonists | KING'S COLLEGE LONDON (GB) | 2017-11-16 | — | — | US | disclosed |
| US-6358995-B1 | AGONIST FOR RETINOIC ACID RECEPTORS; CAN BE SUBSTITUTED FOR RETINOIC ACID AS PREVENTIVE AND THERAPEUTIC DRUGS FOR VARIOUS DISEASES OR CANCERS, SUCH AS ACUTE PROMYELOCYTIC LEUKEMIA. | EISAI CO., LTD. (JP) | 2002-03-19 | — | — | US | disclosed |
| US-6355669-B1 | THERAPY FOR KIDNEY DISEASE USING BENZOIC ACID COMPOUND | EISAI CO., LTD. (JP) | 2002-03-12 | — | — | US | disclosed |
| US-6258811-B1 | ADMINISTERING RETINOIC ACID RECEPTOR AGONIST | EISAI CO., LTD. (JP) | 2001-07-10 | — | — | US | disclosed |
| US-6121309-A | SUCH AS 4-(2-(5-(7-FLUORO-4-TRIFLUOROMETHYLBENZOFURAN-2-YL)PYRROLYL)) BENZOIC ACID; RETINOIC ACID RECEPTOR AGONISM | EISAI CO., LTD. (JP) | 2000-09-19 | — | — | US | disclosed |
| US-6110959-A | A RETINOIC ACID RECEPTOR AGONIST | EISAI CO., LTD. (JP) | 2000-08-29 | — | — | US | disclosed |
| EP-1025857-A1 | RETINOIC ACID AGONISTS AS PREVENTIVE AND THERAPEUTIC AGENTS FOR NEPHRITIS | Eisai Co., Ltd. (JP) | 2000-08-09 | — | — | EP | disclosed |
| EP-0930075-A1 | METHODS FOR PREVENTING, INHIBITING OR TREATING GRAFT REJECTION REACTIONS IN GRAFT-VERSUS-HOST DISEASE (GVHD) AND ORGAN TRANSPLANTATION | Eisai Co., Ltd. (JP) | 1999-07-21 | — | — | EP | disclosed |
| EP-0889032-A1 | FUSED-RING CARBOXYLIC ACID DERIVATIVES | Eisai Co., Ltd. (JP) | 1999-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130337-A1 | Bicycloheteroaryl-Heteroaryl-Benzoic Acid Compounds as Retinoic Acid Receptor Beta (RARBeta) Agonists | RARB, RARA, RXRB | RARA 2/4885RARB 1/4885RARG 4/4885 |
| US-20200131165-A1 | Bicycloheteroaryl-Heteroaryl-Benzoic Acid Compounds as Retinoic Acid Receptor Beta (RARBeta) Agonists | RARB, RARA, RXRB | RARA 2/4885RARB 1/4885RARG 4/4885 |
| US-20170327489-A1 | Bicycloheteroaryl-Heteroaryl-Benzoic Acid Compounds as Retinoic Acid Receptor Beta (RARBeta) Agonists | RARB, RARA, RXRB | RARA 2/4885RARB 1/4885RARG 4/4885 |
| US-10385044-B2 | Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists | RARB, RARA, RARG | RARA 2/4885RARB 1/4885RARG 3/4885 |
| US-10752616-B2 | Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists | RARB, RARA, RXRB | RARA 2/4885RARB 1/4885RARG 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.